Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ublituximab + umbralisib + TG-1501
- Development stage
- Unknown
- Lead developer
- TG Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination regimen of two novel agents—ublituximab, a glycoengineered anti-CD20 monoclonal antibody, and umbralisib, a dual phosphoinositide 3-kinase delta (PI3Kδ) and casein kinase 1 epsilon (CK1ε) inhibitor—together with TG-1501 (cosibelimab), an anti-PD-L1 monoclonal antibody, under investigation for the treatment of various B-cell malignancies and potentially autoimmune/inflammatory disease. Ublituximab targets CD20 on B-cells, inducing cytotoxicity and apoptosis. Umbralisib selectively inhibits PI3Kδ and CK1ε, key targets in B-cell malignancies and immune regulation. TG-1501 (cosibelimab) blocks PD-L1-mediated immune evasion in the tumor microenvironment. The combination is being explored for efficacy and tolerability, aiming for improved disease control and reduced toxicities compared to existing therapies[1][3][4][5][8].
- Brand names
- BriumviUkoniq
- Other names
- U2U-2U 2ublituximab-xiiy
02
Targets
CSNK1E (Casein kinase I isoform epsilon)CD20 (B-lymphocyte antigen CD20)CD274 (Programmed cell death protein 1 ligand 1)PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on ublituximab + umbralisib + TG-1501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ublituximab + umbralisib + TG-1501.